AbCellera jumps 22% on positive trial data

AbCellera Biologics shares gained about 22% after the company reported positive clinical trial results. The move marks one of the larger single-day advances for the antibody discovery firm, which has been shifting from a partnership-based discovery model toward developing its own clinical-stage programmes. Further detail on the trial endpoints and next regulatory steps was not disclosed in the initial coverage.